Investment Thesis
Haemonetics demonstrates excellent profitability with 59.7% gross margins and 11.9% net margins, coupled with exceptional free cash flow generation of $207.2M (21% FCF margin). The company maintains a strong financial position with $363.4M cash, manageable leverage (1.34x debt/equity), and solid interest coverage, providing a stable foundation. However, flat revenue growth is a material concern that limits confidence; the 44.5% EPS growth appears driven by operational leverage and share optimization rather than business expansion.
Strengths
- Industry-leading profitability metrics with 59.7% gross margin and 11.9% net margin
- Exceptional free cash flow generation of $207.2M with 21% FCF margin, demonstrating superior cash conversion
- Strong balance sheet with $363.4M cash, reasonable 1.34x debt/equity ratio, and 5.0x interest coverage ratio
- Efficient capital allocation with minimal capex ($15.1M) relative to operating cash flow
- Healthy liquidity ratios (1.75x current, 1.15x quick) providing financial flexibility
Risks
- Zero revenue growth YoY signals stagnation or market headwinds in core business
- EPS growth driven by operational leverage and capital optimization rather than organic revenue expansion, which is unsustainable
- Elevated debt/equity ratio of 1.34x limits financial flexibility for strategic investments or downturns
- Low ROA of 4.7% indicates inefficient asset deployment relative to $2.5B asset base
- No insider trading activity in last 90 days may indicate limited management confidence or conviction in near-term outlook
Key Metrics to Watch
- Revenue growth trajectory and return to positive YoY growth
- Operating cash flow sustainability as the company's primary strength
- Debt reduction strategy to optimize leverage ratios below 1.2x
- Gross margin preservation amid potential pricing pressures
- Capital allocation decisions (buybacks vs. debt paydown vs. strategic investments)
Financial Metrics
Revenue
987.7M
Net Income
117.5M
EPS (Diluted)
$2.46
Free Cash Flow
207.2M
Total Assets
2.5B
Cash
363.4M
Profitability Ratios
Gross Margin
59.7%
Operating Margin
18.2%
Net Margin
11.9%
ROE
12.9%
ROA
4.7%
FCF Margin
21.0%
Balance Sheet & Liquidity
Current Ratio
1.75x
Quick Ratio
1.15x
Debt/Equity
1.34x
Debt/Assets
0.0%
Interest Coverage
5.01x
Long-term Debt
1.2B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-10T23:45:25.424058 |
Data as of: 2025-12-27 |
Powered by Claude AI